Within the increasingly crowded field of pharmacogenomics, Acadia Pharmaceuticals Inc. sees its Receptor Selection and Amplification Technology (R-SAT) as complementary to SNP analysis and hopes to exploit this combination to characterize the function of drug targets in individual patients.

The company last week announced the formation of a subsidiary, Acadia Pharmacogenomics Inc., that will focus on improving clinical development. The new unit will seek to establish partnerships with companies involved in SNP analysis.